The osteoclast, bone remodelling and treatment of metabolic bone disease
- 23 September 2012
- journal article
- review article
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 42 (12), 1332-1341
- https://doi.org/10.1111/j.1365-2362.2012.02717.x
Abstract
Bone remodelling maintains skeletal integrity by osteoclasts removing foci of damaged bone and osteoblasts replacing them with new bone. Diseases associated with increased bone resorption have increased remodelling often with inadequate bone formation and increased risk of fracture. New therapies are needed for these diseases to reduce resorption and increase formation. The molecular mechanisms regulating osteoclast and osteoblast functions have become better understood in the past 20 years and have led to questioning of the long-held notion that osteoblastic cells have the dominant regulatory role over osteoclastic cells in bone remodelling. Here, we review current knowledge of how osteoclast formation and functions are regulated and describe how enhanced understanding of these has led to development of new drugs for the management of common bone diseases characterized by increased bone resorption. Osteoclast formation and functions are regulated by cytokines, especially receptor activator of NF-κB ligand (RANKL) and macrophage-colony-stimulating factor (M-CSF). The differentiation, activity and lifecycle of osteoclasts are regulated in part by other cells that reside within the bone. These include osteoblasts, osteocytes and immune cells, which express these cytokines in response to most factors that promote bone resorption. RANKL and M-CSF activate numerous signalling pathways, which are potential targets for therapeutic intervention. Importantly, osteoclastic cells also function as positive and negative regulators of osteoblastic bone formation. There are multiple targets within osteoclasts for pharmacologic intervention to prevent bone loss in osteoporosis and other resorptive bone diseases. However, novel therapies could also affect osteoblastic cell functions.Keywords
This publication has 73 references indexed in Scilit:
- Matrix-embedded cells control osteoclast formationNature Medicine, 2011
- Cellular mechanisms of bone remodelingReviews in Endocrine and Metabolic Disorders, 2010
- The amazing osteocyteJournal of Bone and Mineral Research, 2010
- T Lymphocytes Amplify the Anabolic Activity of Parathyroid Hormone through Wnt10b SignalingCell Metabolism, 2009
- TGF-β1–induced migration of bone mesenchymal stem cells couples bone resorption with formationNature Medicine, 2009
- Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasisNature, 2009
- Functions of RANKL/RANK/OPG in bone modeling and remodelingArchives of Biochemistry and Biophysics, 2008
- Eph-Ephrin Bidirectional Signaling in Physiology and DiseaseCell, 2008
- Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systemsNature Reviews Immunology, 2007
- Epidemiology and outcomes of osteoporotic fracturesThe Lancet, 2002